---
title: "OSTX.US (OSTX.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/OSTX.US/news.md"
symbol: "OSTX.US"
name: "OSTX.US"
parent: "https://longbridge.com/zh-HK/quote/OSTX.US.md"
datetime: "2026-03-16T10:10:39.742Z"
locales:
  - [en](https://longbridge.com/en/quote/OSTX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OSTX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OSTX.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/OSTX.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/OSTX.US/news.md)


# OSTX.US (OSTX.US) — 相關新聞

### [OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting | OSTX Stock News](https://longbridge.com/zh-HK/news/278385246.md)
*2026-03-09T03:40:00.000Z*
> OS Therapies Inc. announced that the FDA has elevated its Type D Biomarker Meeting to a Type B pre-BLA Meeting for its O

### [OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings](https://longbridge.com/zh-HK/news/276133518.md)
*2026-02-17T14:01:16.000Z*
> OS Therapies shares rise following the announcement of a 2026 timeline for regulatory filings of its OST-HER2 treatment 

### [OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma | OSTX Stock News](https://longbridge.com/zh-HK/news/276114753.md)
*2026-02-17T03:00:00.000Z*
> OS Therapies Inc. (NYSE American: OSTX) has provided a global regulatory update for its immunotherapy OST-HER2, aimed at

### [OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies | OSTX Stock News](https://longbridge.com/zh-HK/news/274852321.md)
*2026-02-04T09:45:00.000Z*
> OS Therapies Inc. celebrates the reauthorization of the Pediatric Priority Review Voucher Program, which will enhance re

### [OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma | OSTX Stock News](https://longbridge.com/zh-HK/news/274504631.md)
*2026-02-02T03:00:00.000Z*
> OS Therapies Inc. has initiated a Biologics License Application (BLA) submission to the FDA for OST-HER2, aimed at preve

### [OS Therapies Bone Cancer Trial Data Strengthens FDA Case](https://longbridge.com/zh-HK/news/272731326.md)
*2026-01-15T17:30:21.000Z*
> OS Therapies Incorporated (NYSE:OSTX) announced positive trial data for its OST-HER2 immunotherapy in bone cancer, suppo